Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company

Refine Search
Americas
Bristol-Myers Squibb has sued India-based generic maker Alembic over claims that a copycat of the blockbuster leukaemia drug Sprycel, infringes a pair of patents.   4 October 2021
Big Pharma
A unit of Hong-Kong based Sihuan Pharmaceutical Holdings has filed a lawsuit in Beijing accusing private equity firm CBC Group of stealing trade secrets.   30 September 2021
Big Pharma
Pharma giant Novartis has filed a patent suit against Crystal Pharmaceuticals after the rival sought to create a generic version of its heart failure drug Entresto.   30 September 2021
Americas
With the significant growth of cannabinoid IP in the past few years, eyes are now on the emerging psychedelics market as the next frontier for IP protection. Gretchen Temeles of Hiller and Timothy Schlidt of Palo Santo Ventures discuss the issues.   30 September 2021
Americas
Wholesale buyers of MSD’s cholesterol treatment Zetia have asked a Virginia court to recertify their class status and move to trial following a recent fourth circuit ruling that reversed the court’s prior certification.   28 September 2021
Generics
Pfizer subsidiary Anacor has filed five lawsuits targeting drug manufacturers looking to manufacture generic versions of its eczema treatment Eucrisa.   28 September 2021
Biotechnology
Over the past year, the life sciences sector has proved to be of vital importance in the fight against COVID-19. Now more than ever, it is imperative that IP professionals are best positioned to protect and leverage innovation in this fast-paced industry.   28 September 2021
Americas
Law firm Cozen O’Connor has hired patent counsellor Todd Buck to lead trade secret proceedings at its IP and business law practices in Washington DC.   24 September 2021
Americas
The US Patent Trial and Appeal Board has confirmed the validity of three remaining Medtronic patents challenged by rival medical device manufacturer Axonics.   23 September 2021
Americas
Mexico’s updated IP laws seek to avoid the patentability of plants obtained by essentially biological processes—creating issues for plant rights owners, explains Corina Silva of Uhthoff, Gómez Vega & Uhthoff.   23 September 2021